RxDoctor Payments Data

Alpa Shah, MD

Pulmonary Disease · Scottsdale, AZNPI 1881736973

Payments from drug & device makers

$1,209in general payments, 2019–2025

Across 44 payments — averaging $27.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$195
  • Insmed, Inc.$193
  • AstraZeneca$125
  • AbbVie$125
  • Regeneron Healthcare Solutions, Inc.$122
  • Shionogi Inc$115
  • plus $335 from 5 others

What the payments were for

  • Food & beverage$1,17597%
  • Education$343%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,209 in reported general payments places this provider in the 35th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$180,989
Medicare patients
479
Services billed
2,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter312$328,187
Breo ElliptaFluticasone/Vilanterol124$93,779
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr49$29,826
Advair HfaFluticasone Propion/Salmeterol36$25,076
Spiriva RespimatTiotropium Bromide15$19,397
Incruse ElliptaUmeclidinium Bromide27$19,340
Spiriva HandihalerTiotropium Bromide13$19,330
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$18,962
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$14,153
SymbicortBudesonide/Formoterol Fumarate24$13,356
Pirfenidone16$11,369
EliquisApixaban13$8,107
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$6,789
Roflumilast64$5,974
Arnuity ElliptaFluticasone Furoate11$5,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$195$476,561523 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$30$33,55127 claims
AstraZenecaBreztri Aerosphere, Symbicort$125$32,31842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 250 pulmonary disease providers in Arizona.

Other pulmonary disease in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →